Promising Pathway Act 2.0

The Promising Pathway Act 2.0 creates a new FDA pathway for conditional approval of drugs treating rare, progressive, and serious diseases with substantial unmet medical need. It requires sponsors to provide evidence of safety and preliminary effectiveness, establish observational patient registries, and use specific labeling for conditionally approved drugs. The law mandates coverage without cost sharing by private health insurers and federal health care programs for patients with the intended condition. Conditional approval lasts up to 8 years total, with renewal requirements based on additional evidence and registry data, and the FDA can withdraw approval if safety concerns arise or requirements aren't met.